Associations of PGK1 promoter hypomethylation and PGK1-mediated PDHK1 phosphorylation with cancer stage and prognosis: a TCGA pan-cancer analysis

Shao, Fei; Yang, Xueying; Wang, Wei; Wang, Juhong; Guo, Wei; Feng, Xiaoli; Shi, Susheng; Xue, Qi; Gao, Shugeng; Gao, Yibo; Lu, Zhimin; He, Jie

doi:10.1186/s40880-019-0401-9

Table 1 Associations of PGK1 S203 and PDHK1 T338 phosphorylation levels with clinicopathologic characteristics in patients with BRCA, LIHC, LUAD, STAD and ESCA

From: Associations of PGK1 promoter hypomethylation and PGK1-mediated PDHK1 phosphorylation with cancer stage and prognosis: a TCGA pan-cancer analysis

Cancer type	Characteristic	Total (cases)	PGK1 pS203 (IHC staining score)			PDHK1 pT338 (IHC staining score)
Cancer type	Characteristic	Total (cases)	Mean	95% CI	P value	Mean	95% CI	P value
BRCA	Age (years)				0.478			0.975
	≤ 60	96	4.70	4.34–5.06		4.99	4.60–5.38
	> 60	49	4.92	4.41–5.42		5.00	4.47–5.53
	TNM stage^a				0.027			0.018
	I/II	95	4.54	4.18–4.90		4.73	4.34–5.11
	III/IV	48	5.23	4.73–5.73		5.52	4.99–6.06
LIHC	Age (years)
	≤ 60	75	4.28	3.91–4.65	0.615	4.31	3.96–4.66	0.406
	> 60	110	4.42	4.06–4.78		4.52	4.19–4.85
	Gender				0.138			0.365
	Male	159	4.44	4.17–4.71		4.47	4.22–4.72
	Female	26	3.88	3.10–4.67		4.15	3.39–4.92
	TNM stage^b				0.643			0.226
	I/II	73	4.18	3.81–4.55		4.16	3.83–4.50
	III/IV	104	4.30	3.95–4.64		4.46	4.13–4.79
LUAD	Age (years)				0.763			0.385
	≤ 60	84	4.71	4.44–4.99		4.85	4.54–5.15
	> 60	95	4.78	4.46–5.10		4.65	4.34–4.97
	Gender				0.722			0.700
	Male	104	4.72	4.45–4.99		4.71	4.42–5.00
	Female	75	4.79	4.45–5.14		4.79	4.45–5.14
	TNM stage				0.339			0.236
	I/II	105	4.65	4.36–4.94		4.62	4.33–4.91
	III/IV	74	4.86	4.54–5.18		4.89	4.56–5.22
STAD	Age (years)				0.665			0.638
	≤ 60	56	4.55	4.18–4.93		4.61	4.21–5.01
	> 60	39	4.69	4.14–5.24		4.44	3.82–5.05
	Gender				0.149			0.593
	Male	60	4.78	4.39–5.18		4.47	4.01–4.92
	Female	35	4.31	3.81–4.82		4.66	4.14–5.18
	TNM stage^c				0.356			0.195
	I/II	24	4.88	4.19–5.56		4.96	4.26–5.66
	III/IV	69	4.54	4.17–4.90		4.45	4.06–4.84
ESCA	Age (years)				0.781			0.089
	≤ 60	112	4.58	4.23–4.93		4.63	4.30–4.96
	> 60	102	4.65	4.33–4.97		5.03	4.71–5.34
	Gender				0.559			0.216
	Male	176	4.58	4.31–4.84		4.76	4.50–5.01
	Female	38	4.76	4.23–5.29		5.13	4.56–5.70
	TNM stage				0.006			0.008
	I/II	98	4.26	3.89–4.62		4.49	4.14–4.84
	III/IV	116	4.91	4.61–5.22		5.1	4.81–5.40

BRCA breast carcinoma, LIHC liver hepatocellular carcinoma, LUAD lung adenocarcinoma, STAD stomach adenocarcinoma, ESCA esophageal carcinoma, 95% CI 95% confidence interval, PGK1 pS203 PGK1 S203 phosphorylation level, PDHK1 pT338 PDHK1 T338 phosphorylation level
^aThe data of TNM stage in BRCA were available in 143 patients
^bThe data of TNM stage in LIHC were available in 177 patients
^cThe data of TNM stage in STAD were available in 93 patients

Back to article page

ISSN: 2523-3548

Contact us

General enquiries: info@biomedcentral.com

Cancer Communications

Contact us